Caplin Point Laboratories files SEBI Takeover Regulations disclosure (Reg 31(4))
Caplin Point Laboratories Limited submitted a Regulation 31(4) disclosure to NSE on 16 June 2026. Regulation 31(4) requires disclosure by a target company when the acquirer crosses a 5% shareholding threshold or announces an open offer. The substance of this acquisition - including the buyer's identity, consideration, number of shares, and timeline - is not yet publicly detailed in accessible sources.
Why it mattersThe filing triggers mandatory regulatory transparency under SEBI's takeover code; counsel should obtain the full disclosure from the exchange or company to assess materiality, open offer obligations, and minority shareholder protections.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Caplin Point Laboratories SEBI Takeover Disclosure · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Yatharth Hospital & Trauma Care Services Limited: News Verification28 Aug 2026
- Trilegal acts on Berry Street - Healthify merger27 Aug 2026
- ChrysCapital-backed KIMS in talks to acquire minority stake in Renova Hospitals for $52M25-26 Aug 2026 · $52 million
- Mankind Pharma Limited: Other Restructuring26 Aug 2026
- Mankind Pharma Limited: Outcome of Board Meeting26 Aug 2026